Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer

Postmenopausal women with hormone-receptor–positive breast cancer who had received 5 years of adjuvant endocrine therapy were randomly assigned to an additional 2 years or 5 years of therapy with the aromatase inhibitor anastrozole. No between-group differences were noted in disease-free survival, b...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-07, Vol.385 (5), p.395-405
Hauptverfasser:	Gnant, Michael, Fitzal, Florian, Rinnerthaler, Gabriel, Steger, Guenther G, Greil-Ressler, Sigrun, Balic, Marija, Heck, Dietmar, Jakesz, Raimund, Thaler, Josef, Egle, Daniel, Manfreda, Diether, Bjelic-Radisic, Vesna, Wieder, Ursula, Singer, Christian F, Melbinger-Zeinitzer, Elisabeth, Haslbauer, Ferdinand, Sevelda, Paul, Trapl, Harald, Wette, Viktor, Wimmer, Kerstin, Gampenrieder, Simon P, Bartsch, Rupert, Kacerovsky-Strobl, Stephanie, Suppan, Christoph, Brunner, Christine, Deutschmann, Christine, Soelkner, Lidija, Fesl, Christian, Greil, Richard
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants Administration, Oral Aged Anastrozole Anastrozole - administration & dosage Anastrozole - adverse effects Antineoplastic Agents, Hormonal - administration & dosage Antineoplastic Agents, Hormonal - therapeutic use Aromatase Aromatase Inhibitors - administration & dosage Aromatase Inhibitors - adverse effects Bone cancer Breast Cancer Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - surgery Cancer therapies Chemotherapy, Adjuvant Colorectal carcinoma Disease-Free Survival Endocrine therapy Fractures Fractures, Bone - epidemiology Fractures, Bone - etiology General & Internal Medicine Hematology Humans Kaplan-Meier Estimate Life Sciences & Biomedicine Mammography Medicine, General & Internal Middle Aged Neoplasm Recurrence, Local - prevention & control Oncology Osteoporosis Patients Post-menopause Postmenopause Prospective Studies Receptors, Estrogen Receptors, Progesterone Science & Technology Survival Tamoxifen - therapeutic use Treatments in Oncology Ultrasonic imaging Womens health
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Postmenopausal women with hormone-receptor–positive breast cancer who had received 5 years of adjuvant endocrine therapy were randomly assigned to an additional 2 years or 5 years of therapy with the aromatase inhibitor anastrozole. No between-group differences were noted in disease-free survival, but patients in the 5-year group had more bone fractures.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2104162